Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents

Current Cardiology Reports

Volumn 5, Issue 4, 2003, Pages 310-317

  Schroeder, Walter S ^a   Gandhi, Pritesh J ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; AMINOCAPROIC ACID; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; PROTAMINE SULFATE; RETEPLASE; REVIPARIN; STREPTOKINASE; TENECTEPLASE; TINZAPARIN; TIROFIBAN; UROKINASE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; TICLOPIDINE;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTRAOCULAR HEMORRHAGE; MEDICATION ERROR; PHARMACODYNAMICS; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; EMERGENCY HEALTH SERVICE; SYNDROME; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGINA, UNSTABLE; EMERGENCY MEDICAL SERVICES; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SYNDROME; TICLOPIDINE;

EID: 0642369685     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-003-0068-2     Document Type: Review

References (36)

1. Ryan TJ, Antman EM, Brooks NH, et al.: 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999, 100:1016-1030.
2. Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2002, 106:1893-1900.
3. Brennan TA, Leape LL, Laird NM, et al.: Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med 1991, 324:370-376.
4. Freedman JE, Becker RC, Adams JE, et al.: Medication errors in acute cardiac care: an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. Circulation 2002, 106:2623-2629.
5. Scarborough RM, Kleiman NS, Phillips DR: Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999, 100:437-444.
6. Madan M, Berkowitz SD, Tcheng JE: Glycoprotein IIb/IIla integrin blockade. Circulation 1998, 98:2629-2635.
7. Tcheng JE: Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000, 139:S38-S45.
8. Lincoff AM, Tcheng JE, Califf RM, et al.: Standard versus low-dose weight-adiusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Am J Cardiol 1997, 79:286-291.
9. Tcheng JE, Ellis SG, George BS, et al.: Pharmcodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994, 90:1757-1764.
10. Smith BS, Gandhi PJ: Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure. J Thromb Thrombolysis 2001, 11:39-48.
11. Blankenship JC: Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999, 138:287-296.
12. Leclerc JR: Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Crit Care Med 2002, 30:S332-S340.
13. Rao AK, Pratt C, Berke A, et al.: Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988, 11:1-11.
14. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994, 300:956 961.
15. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages in ischemic complications of percutaneous coronary revascularization. The EPILOG investigation. N Engl J Med 1997, 336:1689 1696.
16. Smith SC Jr., Dove JT, Jacobs AK, et al.: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001, 103:3019-3041.
17. Frilling B, Zahn R, Fraiture B, et al.: Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 2002, 89:450-452.
18. Mascelli MA, Lance ET, Damaraju L, et al.: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998, 97:1680-1688.
19. Lemmer JH, Metzdorff MT, Krause AH, et al.: Emergency coronary artery bypass graft surgery in abciximab-treated patients. Ann Thorac Surg 2000, 66:90-95.
20. Alvarez JM: Emergency coronary bypass graft in for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab. J Thorac Cardiovasc Surg 1998, 115:472-473.
21. Jeurgens CP, Yeung AC, Oesterle SN: Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol 1997, 80:74-75.
22. Li YF, Spencer FA, Becker RC: Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition. Am Heart J 2001, 142:204-210.
23. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
24. Hirsh J, Warkentin TE, Shaughnessy SG, et al.: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001, 119:64S-94S.
25. Inverso SM, Cohen M, Antman EM, et al.: Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. 50th Annual Scientific Session of the American College of Cardiology. Orlando, FL; March 18 21, 2001.
26. Massonnet-Castel S, Pelissier E, Bara L, et al.: Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986, 16:139-146.
27. Makris M, Hough RE, Kitchen S: Poor reversal of low molecular weight heparin by protamine. Br J Haematol 2000, 108:884-885.
28. Wolzt M, Weltermann A, Nieszpaur-Los M, et al.: Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 1995, 73:439-443.
29. Van Ryn-McKenna J, Cai L, Ofosu FA, et al.: Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 1990, 63:271-274.
30. Crowther MA, Berry LR, Monagle PT, et al.: Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002, 116:178-186.
31. Fareed J, Jeske W, Hoppensteadt D, et al.: Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998, 82:3L-10L.
32. Schick BP, Gradowski JF, San Antionio JD, et al.: Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans. Thromb Haemost 2001, 85:482-487.
33. Lovenox package insert. Aventis; Bridgewater, NJ; 2002.
34. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999, 354:716-722.
35. Becker RC, Gore JM, Rubinson M, et al.: Association between body weight and in-hospital clinical outcome following thrombolytic therapy: a report from the national registry of myocardial infarction. J Thromb Thrombolysis 1995, 2:231-237.
36. Sane DC, Califf RM, Topol EJ, et al.: Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989, 111:1010-1022.